For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Sty ...

With a market cap of $15.8 billion, The Cooper Companies, Inc. (COO) is a global medical device company specializing in contact lenses and women’s health care solutions. Through its CooperVision and CooperSurgical segments, it offers advanced vision-correction lenses as well as fertility, genomics, and contraceptive products. Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Cooper Companies fits this criterion perfectly. The company serves healthcare professionals ...

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Merit Medical (MMSI) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and ou ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zac ...

Have you evaluated the performance of The Cooper Companies' (COO) international operations during the quarter that concluded in October 2025? Considering the extensive worldwide presence of this surgical and contact lens products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influ ...

Company Segments - Cooper Companies operates through two segments: CooperVision, focusing on contact lenses, and CooperSurgical, specializing in fertility and women's health[21]. - CooperSurgical offers over 600 products and services, including medical devices for gynecology and obstetrics, and fertility products used in IVF processes[23][31]. Product Innovations - CooperVision's MiSight 1 day lens is the first FDA-approved product to slow myopia progression in children aged 8-12, with approvals in China and Japan expected in 2021 and 2025 respectively[22][30]. - CooperSurgical's Paragard IUD is a hormone-free contraceptive option available in the U.S., competing with hormonal IUDs and other birth control methods[36]. - CooperVision's Biofinity brand is its highest-grossing product, with a focus on silicone hydrogel lenses for various vision correction needs[26]. Research and Development - The company employs approximately 500 people in research and development, focusing on new contact lens designs and manufacturing technologies[44]. - CooperSurgical's research and development includes innovations in instruments, devices, and digital services to improve clinical outcomes[45]. - The company is committed to expanding its integrated solutions model in fertility and women's health through strategic transactions and product development[34]. Market Trends - The market for contact lenses is expanding, particularly in myopia management, with CooperVision investing in education to increase awareness among practitioners and families[29][30]. - CooperSurgical anticipates a shift towards group practices and corporate ownership in OB/GYN and fertility clinics, which may enhance supply chain control and vendor standardization[39]. - The contact lens industry is evolving with new distribution models and online services, which may conflict with CooperVision's strategy[145]. Regulatory Compliance - The majority of medical devices marketed by the company have received FDA clearance through the 510(k) process or approval through the PMA process[51]. - The company maintains ISO 13485 certification and CE marks for its products, which are necessary for marketing medical devices in the EU[61]. - Compliance with general safety and performance requirements is essential for obtaining CE marks, which are necessary for marketing in the EU[65]. - The company must undergo conformity assessments and audits by EU notified bodies to ensure compliance with the EU IVDR for current and future tests[69]. - The FDA's Cybersecurity requirements for medical devices include a comprehensive risk management plan and a Software Bill of Materials (SBOM) to support vulnerability tracking[58]. International Operations - The company derives approximately 50% of its net sales from international markets, indicating a strong reliance on foreign operations for growth[109]. - In Asia Pacific, regulatory approval processes for medical devices are complex and vary significantly by country, often requiring proof of home country approval prior to registration, which can delay product launches[73]. - The NMPA in China mandates physical testing and in-country clinical trials for medical device registrations, impacting the time to market[74]. Financial Risks - The company faces significant risks from current market conditions, including recessionary pressures that could adversely affect liquidity and financial condition[105]. - Inflationary pressures have led to increased costs, which may not be fully passed on to customers, impacting profitability[108]. - Pricing pressure from competitors and changes in third-party reimbursement could adversely affect demand for CooperSurgical products, impacting operating results[126]. Cybersecurity and IT Risks - Cybersecurity threats are increasing, with potential disruptions to information technology systems that could lead to significant financial and reputational harm[121]. - The company is in the process of implementing new ERP systems, which are costly and complex, potentially impacting financial reporting and commercial activities[123]. Employee and Workplace Culture - The company has implemented a Connection & Belonging strategy to foster an inclusive work environment, promoting diversity and innovation[98]. - The company emphasizes employee training and development, offering job-specific training and regular feedback to enhance workplace culture[100]. - The company is experiencing challenges in recruiting and retaining skilled personnel, which could disrupt operations[159]. Competition and Market Position - CooperVision operates in a highly competitive environment, facing significant competition from major players like Johnson & Johnson and Alcon, which may have greater resources[143]. - CooperSurgical competes in the family and women's health care market, focusing on technological and scientific advances, product quality, and customer service[146]. Regulatory Challenges - The evolving regulatory landscape in the EU and UK may significantly impact business operations and compliance costs[186]. - Changes in healthcare legislation, such as the ACA and recent EU regulations, could materially impact the company's revenue and operational costs[210][213]. - Compliance with evolving environmental, social, and governance (ESG) regulations may incur significant costs and affect the company's operations[156].

Cooper Companies (NASDAQ:COO) stock rose Friday after the company reported better-than-expected fourth-quarter earnings and upbeat financial guidance.The company also said it is conducting a formal review of the company’s portfolio, structure, strategy, operations, and capital priorities.The review aims to identify opportunities to streamline the business and unlock additional long-term value, including potential partnerships, joint ventures, divestitures, mergers, or other transactions.Also Read: Activist ...

Key Takeaways COO posted Q4 EPS and revenue beat, driven by operational gains and stronger product demand.MyDay contract wins and solid MiSight growth supported revenue increases across CVI.CSI saw broader gains as PARAGARD rebounded and fertility benefited from genomics strength.The Cooper Companies, Inc. (COO) delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.15, which improved 11% year over year. The figure beat the Zacks Consensus Estimate of $1.11 by 3.6%. Operational improve ...

U.S. stock futures were fluctuating on Friday after ending in a mixed manner on Thursday. Futures of major benchmark indices were mixed.Investors await the September reading of the Federal Reserve's preferred inflation gauge, the PCE price index, a marquee event delayed by the recent government shutdown.Meanwhile, according to Challenger, Gray & Christmas, U.S. job cuts fell 53% month-over-month in November, but the total of 71,321 remained 24% higher than a year ago, reflecting a cautious labor market grap ...

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Victoria’s Secret & Co. (NYSE:VSCO) to report a quarterly loss of 59 cents per share on revenue of $1.41 billion before the opening bell, according to data from Benzinga Pro. Victoria’s Secret shares rose 2.2% to $42.50 in after-hours trading.Hewlett Packard Enterprise Co. (NYSE:HPE) reported mixed fourth-quarter financial results and issued weak first-quart ...